The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis
Open accessAbstract
The target of a first-line tuberculosis drug that acts against persister bacteria is identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299
Self-citationScorpio, A., & Zhang, Y. (1996) · Nature Medicine · doi:10.1038/nm0696-662 · Cited by 726
Self-citationThe curious characteristics of pyrazinamide: a review.
Zhang, Y., & Mitchison, D. A. (2003) · PubMed · Cited by 723
Self-citationThe action of antituberculosis drugs in short-course chemotherapy
Mitchison, D. A. (1985) · Tubercle · doi:10.1016/0041-3879(85)90040-6 · Cited by 518
Zhang, Y. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg446 · Cited by 477
Self-citationBycroft, M., Hubbard, T. J. P., Proctor, M., Freund, S. M. V., & Murzin, A. G. (1997) · Cell · doi:10.1016/s0092-8674(00)81844-9 · Cited by 407
Mechanisms of Drug Resistance in Mycobacterium tuberculosis
Heym, B., Philipp, W., & Cole, S. T. (1996) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-80166-2_3 · Cited by 379
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis
Scorpio, A., Lindholm-Levy, P., Heifets, L., Gilman, R., Siddiqi, S., Cynamon, M., & Zhang, Y. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.540 · Cited by 333
Self-citationMcCune, R. M., Feldmann, F. M., Lambert, H. P., & McDermott, W. (1966) · The Journal of Experimental Medicine · doi:10.1084/jem.123.3.445 · Cited by 310
Cited by
Platforms for antibiotic discovery
Lewis, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3975 · Cited by 1,445
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
Ribosomal proteins: functions beyond the ribosome
Zhou, X., Liao, W.-J., Liao, J.-M., Liao, P., & Lu, H. (2015) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjv014 · Cited by 743
Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack
Ziegler, S., Pries, V., Hedberg, C., & Waldmann, H. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208749 · Cited by 466
Drug Resistance Mechanisms in Mycobacterium tuberculosis
Palomino, J., & Martin, A. (2014) · Antibiotics · doi:10.3390/antibiotics3030317 · Cited by 442
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells
Dartois, V. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3200 · Cited by 388
Formation, physiology, ecology, evolution and clinical importance of bacterial persisters
Van den Bergh, B., Fauvart, M., & Michiels, J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux001 · Cited by 381
Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis
Coll, F., Phelan, J., Hill-Cawthorne, G. A., Nair, M. B., Mallard, K., Ali, S., Abdallah, A. M., Alghamdi, S., Alsomali, M., Ahmed, A. O., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0029-0 · Cited by 375
Biofilms: Survival and defense strategy for pathogens
Kumar, A., Alam, A., Rani, M., Ehtesham, N. Z., & Hasnain, S. E. (2017) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2017.09.016 · Cited by 368
Dookie, N., Rambaran, S., Padayatchi, N., Mahomed, S., & Naidoo, K. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx506 · Cited by 346
The Normalcy of Dormancy: Common Themes in Microbial Quiescence
Rittershaus, E. S. C., Baek, S.-H., & Sassetti, C. M. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.05.012 · Cited by 340
Scaling up interventions to achieve global tuberculosis control: progress and new developments
Raviglione, M., Marais, B., Floyd, K., Lönnroth, K., Getahun, H., Migliori, G. B., Harries, A. D., Nunn, P., Lienhardt, C., Graham, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60727-2 · Cited by 340
Mechanisms of Pyrazinamide Action and Resistance
Zhang, Y., Shi, W., Zhang, W., & Mitchison, D. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0023-2013 · Cited by 332
Self-citationBacterial persisters: molecular mechanisms and therapeutic development
Niu, H., Gu, J., & Zhang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01866-5 · Cited by 310
Self-citationTargeting Persisters for Tuberculosis Control
Zhang, Y., Yew, W. W., & Barer, M. R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06288-11 · Cited by 271
Self-citationThe Concept of an Ideal Antibiotic: Implications for Drug Design
Gajdács, M. (2019) · Molecules · doi:10.3390/molecules24050892 · Cited by 271
Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target
Zhang, B., Li, J., Yang, X., Wu, L., Zhang, J., Yang, Y., Zhao, Y., Zhang, L., Yang, X., Yang, X., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.003 · Cited by 263
Fighting bacterial persistence: Current and emerging anti-persister strategies and therapeutics
Defraine, V., Fauvart, M., & Michiels, J. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.03.002 · Cited by 222
Metadata
- Authors
- Shi, W., Zhang, X., Jiang, X., Yuan, H., Lee, J. S., Barry, C. E., Wang, H., Zhang, W., & Zhang, Y.
- Venue
- Science
- Published
- 2011-09-16
- Volume
- 333
- Issue
- 6049
- Pages
- 1630-1632
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1975610050
- Cited by
- 514
- References
- 33
- FWCI
- 30.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.